Gujarat Terce Laboratories Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 890385,
    "name": "Guj. Terce Labs.",
    "stock_name": "Guj. Terce Labs.",
    "full_name": "Gujarat Terce Laboratories Ltd",
    "name_url": "stocks-analysis/guj-terce-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "44.03",
    "chg": -0.29,
    "chgp": "-0.65%",
    "dir": -1,
    "prev_price": "44.32",
    "mcapval": "35.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524314,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE499G01013",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "2.65 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/guj-terce-labs-890385-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Guj. Terce Labs. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-guj-terce-labs-fallingrising-3742466",
        "imagepath": "",
        "date": "2025-12-03 00:48:20",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Intraday Price Movements and Volatility</strong></p>\n<p>Despite opening the day with a positive gap of 2.49%, the stock failed to sustain early gains and experienced a sharp reversal. The intraday high was recorded at ₹47.84, representing the initial optimism, but the price subsequently fell to an intraday low of ₹43.25, marking a 7.35% decline from the previous close. This wide trading range of ₹4.59 underscores the heightened volatility that characterised the stock’s performance throughout the day.</p>\n<p>The weighted average price indicates that a larger volume of shares traded closer to the lower end of the day’s range, signalling selling pressure as the session progressed. Such price action suggests that investors were eager to exit positions, contributing to the downward momentum.</p>\n..."
      },
      {
        "title": "Is Guj. Terce Labs. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-guj-terce-labs-overvalued-or-undervalued-3709851",
        "imagepath": "",
        "date": "2025-11-18 08:22:54",
        "description": "As of 17 November 2025, the valuation grade for Guj. Terce Labs. has moved from expensive to very expensive. This indicates a significant deterioration in its valuation outlook, suggesting that the company is overvalued. The key ratios highlight this concern, with a PE ratio of -32.23, a Price to Book Value of 4.39, and an EV to EBITDA of 7.59, all of which signal potential overvaluation when compared to industry norms.\n\nIn comparison to its peers, Guj. Terce Labs. stands out unfavorably; for instance, Sun Pharma has a PE ratio of 36.69 and an EV to EBITDA of 24.22, while Divi's Lab shows a PE of 69.78 and an EV to EBITDA of 52.44. These comparisons further reinforce the notion that Guj. Terce Labs. is not only overvalued but also lagging behind its competitors in terms of financial performance. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -47.76%, contra..."
      },
      {
        "title": "How has been the historical performance of Guj. Terce Labs.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-guj-terce-labs-3683702",
        "imagepath": "",
        "date": "2025-11-09 22:47:36",
        "description": "Answer:\nThe historical performance of Guj. Terce Labs shows a decline in net sales and profitability over the past three years, culminating in a loss in the most recent fiscal year.\n\nBreakdown:\nGuj. Terce Labs reported net sales of 25.18 Cr in March 2021, a significant decrease from 37.54 Cr in March 2020 and 31.03 Cr in March 2019. The total operating income mirrored this trend, remaining at 25.18 Cr in March 2021, down from 37.54 Cr in March 2020. The company's total expenditure, excluding depreciation, was 27.94 Cr in March 2021, which also decreased from 36.86 Cr in March 2020. This led to an operating profit (PBDIT) of -1.96 Cr in March 2021, contrasting with a profit of 0.97 Cr in March 2020 and 0.80 Cr in March 2019. Consequently, the profit before tax fell to -2.53 Cr in March 2021, down from 0.44 Cr in March 2020. The profit after tax also reflected this downturn, resulting in a loss of 2.52 Cr in ..."
      },
      {
        "title": "Are Guj. Terce Labs. latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-guj-terce-labs-latest-results-good-or-bad-3683316",
        "imagepath": "",
        "date": "2025-11-09 19:14:31",
        "description": "Gujarat Terce Laboratories' latest financial results for Q2 FY26 reveal significant operational challenges. The company reported net sales of ₹10.13 crores, reflecting marginal growth of 1.91% sequentially, while year-on-year performance remained essentially flat at 0.20%. However, the most concerning aspect was the sharp contraction in operating profit margins, which fell to 5.33% from 16.40% in the previous quarter, indicating severe operational stress.\n\nNet profit for the quarter was ₹0.45 crores, which represents a substantial decline of 71.88% compared to the previous quarter. This decline in profitability highlights difficulties in cost management, particularly as employee costs rose significantly, consuming nearly 39% of revenues. The company's return on equity (ROE) has also been notably weak, with a recent figure of -15.34%, further underscoring the operational distress.\n\nDespite the company mainta..."
      },
      {
        "title": "Gujarat Terce Laboratories Q2 FY26: Profit Plunge Raises Serious Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/gujarat-terce-laboratories-q2-fy26-profit-plunge-raises-serious-concerns-3682515",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GujaratTerceLab_quaterlyResult_3682515.png",
        "date": "2025-11-08 18:02:17",
        "description": "Gujarat Terce Laboratories Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹32.00 crores, reported deeply concerning quarterly results for Q2 FY26 (Jul-Sep'25), with net profit plummeting 71.88% quarter-on-quarter to ₹0.45 crores from ₹1.60 crores in Q1 FY26. The stock, currently trading at ₹45.98, has collapsed 45.25% over the past year, significantly underperforming both the broader market and its pharmaceutical sector peers."
      },
      {
        "title": "Why is Guj. Terce Labs. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-guj-terce-labs-fallingrising-3676862",
        "imagepath": "",
        "date": "2025-11-06 22:31:09",
        "description": "As of 06-Nov, Gujarat Terce Laboratories Ltd is experiencing a decline in its stock price, currently at Rs 44.15, which reflects a decrease of Rs 1.71 or 3.73%. The stock has been underperforming, having lost 5.07% over the last two days and is trading below all key moving averages, indicating a bearish trend. Additionally, the stock's performance today has underperformed its sector by 2.96%. Over the past week, the stock has decreased by 6.36%, and year-to-date, it has plummeted by 47.94%, showcasing significant underperformance compared to the Sensex, which has gained 6.62% during the same period. There is also a notable decline in investor participation, with delivery volume dropping by 83.32% against the 5-day average, suggesting reduced interest in the stock.\n\nBroader Market Context: In the context of the broader market, Gujarat Terce Laboratories Ltd's recent performance contrasts sharply with the Sen..."
      }
    ],
    "total": 167,
    "sid": "890385",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/gujarat-terce-laboratories-890385"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "07-Jan-2026",
      "details": "Please find enclosed herewith the certificate received from Bigshare Services Private Limited in respect of dematerialisation request received by them for the Company during the period 1 October 2025 to 31 December 2025.",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "28-Dec-2025",
      "details": "Closure of Trading window: Unaudited Financial Results for the quarter ended on 31st March 2025.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for The Unaudited Financial Results For The Third Quarter And Nine Months Ending On 31-12-2025.",
      "datetime": "28-Dec-2025",
      "details": "Gujarat Terce Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2026 inter alia to consider and approve Unaudited Financial results for the third quarter and nine months ending on 31-12-2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Guj. Terce Labs. falling/rising?

2025-12-03 00:48:20

Intraday Price Movements and Volatility Despite opening the day with a positive gap of 2.49%, the stock failed to sustain early gains and experienced a sharp reversal. The intraday high was recorded at ₹47.84, representing the initial optimism, but the price subsequently fell to an intraday low of ₹43.25, marking a 7.35% decline from the previous close. This wide trading range of ₹4.59 underscores the heightened volatility that characterised the stock’s performance throughout the day. The weighted average price indicates that a larger volume of shares traded closer to the lower end of the day’s range, signalling selling pressure as the session progressed. Such price action suggests that investors were eager to exit positions, contributing to the downward momentum. ...

Is Guj. Terce Labs. overvalued or undervalued?

2025-11-18 08:22:54

As of 17 November 2025, the valuation grade for Guj. Terce Labs. has moved from expensive to very expensive. This indicates a significant deterioration in its valuation outlook, suggesting that the company is overvalued. The key ratios highlight this concern, with a PE ratio of -32.23, a Price to Book Value of 4.39, and an EV to EBITDA of 7.59, all of which signal potential overvaluation when compared to industry norms. In comparison to its peers, Guj. Terce Labs. stands out unfavorably; for instance, Sun Pharma has a PE ratio of 36.69 and an EV to EBITDA of 24.22, while Divi's Lab shows a PE of 69.78 and an EV to EBITDA of 52.44. These comparisons further reinforce the notion that Guj. Terce Labs. is not only overvalued but also lagging behind its competitors in terms of financial performance. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -47.76%, contra...

How has been the historical performance of Guj. Terce Labs.?

2025-11-09 22:47:36

Answer: The historical performance of Guj. Terce Labs shows a decline in net sales and profitability over the past three years, culminating in a loss in the most recent fiscal year. Breakdown: Guj. Terce Labs reported net sales of 25.18 Cr in March 2021, a significant decrease from 37.54 Cr in March 2020 and 31.03 Cr in March 2019. The total operating income mirrored this trend, remaining at 25.18 Cr in March 2021, down from 37.54 Cr in March 2020. The company's total expenditure, excluding depreciation, was 27.94 Cr in March 2021, which also decreased from 36.86 Cr in March 2020. This led to an operating profit (PBDIT) of -1.96 Cr in March 2021, contrasting with a profit of 0.97 Cr in March 2020 and 0.80 Cr in March 2019. Consequently, the profit before tax fell to -2.53 Cr in March 2021, down from 0.44 Cr in March 2020. The profit after tax also reflected this downturn, resulting in a loss of 2.52 Cr in ...

Are Guj. Terce Labs. latest results good or bad?

2025-11-09 19:14:31

Gujarat Terce Laboratories' latest financial results for Q2 FY26 reveal significant operational challenges. The company reported net sales of ₹10.13 crores, reflecting marginal growth of 1.91% sequentially, while year-on-year performance remained essentially flat at 0.20%. However, the most concerning aspect was the sharp contraction in operating profit margins, which fell to 5.33% from 16.40% in the previous quarter, indicating severe operational stress. Net profit for the quarter was ₹0.45 crores, which represents a substantial decline of 71.88% compared to the previous quarter. This decline in profitability highlights difficulties in cost management, particularly as employee costs rose significantly, consuming nearly 39% of revenues. The company's return on equity (ROE) has also been notably weak, with a recent figure of -15.34%, further underscoring the operational distress. Despite the company mainta...

Gujarat Terce Laboratories Q2 FY26: Profit Plunge Raises Serious Concerns

2025-11-08 18:02:17

Gujarat Terce Laboratories Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹32.00 crores, reported deeply concerning quarterly results for Q2 FY26 (Jul-Sep'25), with net profit plummeting 71.88% quarter-on-quarter to ₹0.45 crores from ₹1.60 crores in Q1 FY26. The stock, currently trading at ₹45.98, has collapsed 45.25% over the past year, significantly underperforming both the broader market and its pharmaceutical sector peers.

Why is Guj. Terce Labs. falling/rising?

2025-11-06 22:31:09

As of 06-Nov, Gujarat Terce Laboratories Ltd is experiencing a decline in its stock price, currently at Rs 44.15, which reflects a decrease of Rs 1.71 or 3.73%. The stock has been underperforming, having lost 5.07% over the last two days and is trading below all key moving averages, indicating a bearish trend. Additionally, the stock's performance today has underperformed its sector by 2.96%. Over the past week, the stock has decreased by 6.36%, and year-to-date, it has plummeted by 47.94%, showcasing significant underperformance compared to the Sensex, which has gained 6.62% during the same period. There is also a notable decline in investor participation, with delivery volume dropping by 83.32% against the 5-day average, suggesting reduced interest in the stock. Broader Market Context: In the context of the broader market, Gujarat Terce Laboratories Ltd's recent performance contrasts sharply with the Sen...

View All News